- Current report filing (8-K)
May 06 2009 - 8:34AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
To Section 13 or 15 (d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported) - May 6, 2009
NUCRYST
PHARMACEUTICALS CORP.
(Exact
name of registrant as specified in its charter)
Alberta,
Canada
|
|
000-51686
|
|
Not
Applicable
|
(State
or other jurisdiction of
incorporation or
organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
NUCRYST
Pharmaceuticals Corp.
101
College Road East
Princeton,
New Jersey 08540
(Address
of principal executive offices)
Registrant’s
telephone number, including area code:
(609)
228-8210
Not
applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (
see
General
Instruction A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
(Former name or former address, if
changed since last report)
Item
2.02
|
Results
of Operations and Financial
Condition.
|
On
May 6, 2009, NUCRYST Pharmaceuticals Corp. (the “Company”) issued a press
release announcing its financial results for the quarter ended March 31,
2009. The press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
The
information in this Current Report on Form 8-K, including the exhibit attached
hereto, is being furnished to the United States Securities and Exchange
Commission (the “SEC”) and shall not be deemed to be “filed” for any purpose,
nor shall such information or such exhibit be deemed of incorporated by
reference in any filing with the SEC made by the Company under the Securities
Exchange Act of 1934, or the Securities Act of 1933, whether made before or
after the date hereof, regardless of any general incorporation language in such
filing, unless expressly set forth by specific reference to this
filing.
Item
9.01
|
Financial
Statements and Exhibits
|
(d)
Exhibits.
|
|
Description
|
99.1
|
|
Press Release, dated May 6, 2009, titled
“
NUCRYST
announces
2009 first quarter financial
results.”
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Nucryst Pharmaceuticals
Corp.
|
|
|
|
|
|
Date:
May 6, 2009
|
By:
|
/s/
Carol L.
Amelio
|
|
|
|
Carol L.
Amelio
|
|
|
|
Vice
President, General Counsel and Corporate Secretary
|
|
|
|
|
|
Nucryst (NASDAQ:NCST)
Historical Stock Chart
From May 2024 to Jun 2024
Nucryst (NASDAQ:NCST)
Historical Stock Chart
From Jun 2023 to Jun 2024